Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 6/20 | 0.54 |
| ▸ | PPARG | P37231 | 5/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.47 |
| ▸ | PTGIR | P43119 | 1/20 | 0.46 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.46 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11320810 | 0.94 | PPARA (0.62) | PPARAPPARG | |
| SCHEMBL5245979 | 0.90 | ALOX5 (0.47) | PPARAPPARGCYP2D6MTNR1AMTNR1B | |
| SCHEMBL515972 | 0.83 | MAPK1 (0.50) | PPARAPPARG | |
| SCHEMBL30333093 | 0.83 | MAPK1 (0.50) | PPARAPPARG | |
| SCHEMBL14378255 | 0.82 | PPARA (0.52) | PPARAPPARGCYP2D6MTNR1AMTNR1B | |
| SCHEMBL6265367 | 0.82 | PPARA (0.59) | PPARAPPARGPTGIR | |
| SCHEMBL8138064 | 0.80 | CA1 (0.47) | PPARA | |
| SCHEMBL28364877 | 0.79 | PPARA (0.56) | PPARAPPARGCYP2D6MTNR1AMTNR1B | |
| SCHEMBL4568894 | 0.79 | PPARA (0.52) | PPARAPPARGCYP2D6PTGIR | |
| SCHEMBL10699535 | 0.78 | PPARA (0.58) | PPARAPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111465589-B | Compound having fluorene skeleton and method for producing same | 帝人株式会社 | 2024-01-05 | — | — | CN | disclosed |
| US-11339249-B2 | Compound having fluorene skeleton, and method for manufacturing same | TEIJIN LIMITED (JP) | 2022-05-24 | — | — | US | disclosed |
| EP-3747856-A1 | COMPOUND HAVING FLUORENE SKELETON, AND METHOD FOR MANUFACTURING SAME | Teijin Limited (JP) | 2020-12-09 | — | — | EP | disclosed |
| US-20200354517-A1 | COMPOUND HAVING FLUORENE SKELETON, AND METHOD FOR MANUFACTURING SAME | TEIJIN LIMITED (JP) | 2020-11-12 | — | — | US | disclosed |
| CN-111465589-A | Compound having fluorene skeleton and method for producing same | 帝人株式会社 | 2020-07-28 | — | — | CN | disclosed |
| US-8841491-B2 | Method for producing fluorene derivative | TAOKA CHEMICAL CO., LTD. (JP) | 2014-09-23 | — | — | US | disclosed |
| CN-102388012-A | Method for producing fluorene derivative | TAOKA CHEMICAL CO LTD | 2012-03-21 | — | — | CN | disclosed |
| EP-2420485-A1 | METHOD FOR PRODUCING FLUORENE DERIVATIVE | Taoka Chemical Co., Ltd. (JP) | 2012-02-22 | — | — | EP | disclosed |
| US-20120029244-A1 | METHOD FOR PRODUCING FLUORENE DERIVATIVE | TAOKA CHEMICAL CO., LTD. (JP) | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200354517-A1 | COMPOUND HAVING FLUORENE SKELETON, AND METHOD FOR MANUFACTURING SAME | RFT1, AFF1, RER1 | PPARA 1428/4885PPARG 2369/4885CYP2D6 3183/4885 |
| US-20120029244-A1 | METHOD FOR PRODUCING FLUORENE DERIVATIVE | ADH1A, AFF2, AFF1 | PPARA 124/4885PPARG 159/4885CYP2D6 365/4885 |
| US-11339249-B2 | Compound having fluorene skeleton, and method for manufacturing same | RFT1, AFF1, RER1 | PPARA 1428/4885PPARG 2369/4885CYP2D6 3183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.